🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 501575104
- IPO
- 8/21/2020 · $20.00/share
Business: Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body.
Company Contact
- CEO
- Nello Mainolfi
- CFO
- Bruce Jacobs
- Headquarters
- 200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472
- Phone
- 857-285-5300
- Investor Relations
- Bruce Jacobs · 857-285-5300 · investors@kymeratx.com